Trial · NCT07905755
Effect of HMB Supplementation and Vivifrail Exercise on Body Composition, Handgrip Strength and Physical Performance in Women Over 60 Years of Age
NCT07905755, Not applicable, Not yet recruiting, Universidad Autónoma del Estado de Hidalgo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of HMB Supplementation and Vivifrail Exercise on Body Composition, Handgrip Strength and Physical Performance in Women Over 60 Years of Age. Trials, record NCT07905755. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905755
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of HMB Supplementation and Vivifrail Exercise on Body Composition, Handgrip Strength and Physical Performance in Women Over 60 Years of Age
- NCT number
- NCT07905755
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 44 participants, estimated
- Lead sponsor
- Universidad Autónoma del Estado de Hidalgo
- Conditions
- Aging, Muscle Strength, Physical Functional Performance, Body Composition
- Interventions
- Calcium β-hydroxy-β-methylbutyrate (HMB-Ca), Maltodextrin (Placebo), Vivifrail multicomponent exercise program
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in handgrip strength | Baseline, week 6 and week 12 | Maximum handgrip strength (kg) measured with a Jamar hydraulic dynamometer. Higher values indicate greater muscle strength. |
| Secondary | Change in Short Physical Performance Battery (SPPB) score | Baseline, week 6 and week 12 | Total SPPB score (0-12 points), including balance, 4-meter gait speed and 5-times chair stand tests. Higher scores indicate better physical performance. |
| Secondary | Change in appendicular muscle mass | Baseline, week 6 and week 12 | Appendicular muscle mass (kg), calculated as the sum of segmental muscle mass of both arms and both legs estimated by segmental bioelectrical impedance (Tanita BC-545N). |
| Secondary | Change in body fat percentage | Baseline, week 6 and week 12 | Body fat (%) estimated by bioelectrical impedance (Tanita BC-545N). |
| Secondary | Change in calf circumference | Baseline, week 6 and week 12 | Calf circumference (cm) measured following the ISAK protocol. |
| Secondary | Change in relaxed arm circumference | Baseline, week 6 and week 12 | Relaxed arm circumference (cm) measured following the ISAK protocol. |
| Secondary | Change in flexed arm circumference | Baseline, week 6 and week 12 | Flexed and tensed arm circumference (cm) measured following the ISAK protocol. |
| Secondary | Change in waist circumference | Baseline, week 6 and week 12 | Waist circumference (cm) measured following the ISAK protocol. |
| Other | Dietary protein intake | Baseline, week 6 and week 12 | Protein intake (g/kg/day) estimated from three multiple-pass 24-hour dietary recalls (two weekdays and one weekend day), analyzed with Nutrimind software; used as a covariate. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905755
GET https://conductscience.org/api/trials/v1/NCT07905755/registered